According to the ELN recommendations, six genetic mutations have been demonstrated to be of prognostic significance among all AML patients, including mutations in FLT3, NPM1, CEBPA, RUNX1, TP53, and ASXL1 (11). Here, NPM1 is linked to acute myeloid leukemia.